Top Page
Cronos Australia Ltd.
(Sydney:VIT)
Cronos Australia Ltd. (VIT) vs. S&P 500 (SPY)
Cronos Australia Ltd. Business Overview & Revenue Model
Cronos Australia Ltd. Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 123.87M | 117.34M | 66.99M | 1.69M | 123.85K | Gross Profit |
| 34.22M | 25.96M | 25.43M | 872.93K | 116.79K | EBIT |
| 4.87M | 19.86M | 10.19M | -3.91M | -3.83M | EBITDA |
| 7.08M | 20.85M | 10.87M | -486.62K | -3.74M | Net Income Common Stockholders |
| 3.51M | 13.81M | 6.05M | -4.05M | -3.94M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 11.35M | 18.85M | 16.08M | 9.47M | 14.69M | Total Assets |
| 71.28M | 46.90M | 42.87M | 12.69M | 16.23M | Total Debt |
| 11.02M | 1.28M | 5.06M | 2.36M | 2.21M | Net Debt |
| -326.07K | -17.57M | -11.02M | -7.10M | -12.48M | Total Liabilities |
| 32.84M | 11.99M | 16.79M | 3.47M | 2.73M | Stockholders Equity |
| 38.78M | 34.98M | 26.10M | 9.30M | 13.44M |
| Cash Flow | Free Cash Flow | |||
| 6.21M | 8.78M | 13.13M | 1.01M | -5.16M | Operating Cash Flow |
| 7.00M | 9.71M | 13.50M | 1.07M | -4.89M | Investing Cash Flow |
| -13.20M | -837.72K | 2.00M | -160.69K | -515.91K | Financing Cash Flow |
| -1.30M | -6.10M | -1.50M | -262.03K | 19.93M |
Cronos Australia Ltd. Technical Analysis
Cronos Australia Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$45.70M | 20.29 | 4.85% | ― | 5.76% | -79.76% | |
51 Neutral | $5.31B | 3.39 | -40.42% | 2.90% | 18.11% | 2.25% | |
46 Neutral | $6.18M | ― | -21.29% | ― | 80.87% | 82.44% | |
39 Underperform | $9.65M | ― | -164.01% | ― | -18.80% | -46.65% | |
39 Underperform | AU$4.26M | ― | ― | -49.04% | 32.85% | ||
39 Underperform | AU$11.48M | ― | -218.38% | ― | -14.30% | 29.69% |
Cronos Australia Ltd. Corporate Events
Vitura Health Limited has announced the cessation of 106,933 performance rights due to the conditions for these securities not being met or becoming incapable of being satisfied. This development may impact the company’s capital structure and could have implications for stakeholders, as it reflects on the company’s ability to meet certain performance conditions.
Vitura Health Limited, listed on the ASX, has addressed a compliance query from the ASX regarding a trading incident involving its Director, Mr. Robert Iervasi. The company clarified that the trading was technically compliant with its Trading Policy, although an administrative oversight led to the clearance being granted a day earlier than prescribed. The board has decided not to take any disciplinary action, citing that the market was fully informed and the trade was executed at a premium. The company has reiterated its commitment to compliance and has reminded staff of their obligations under the Trading Policy.
Vitura Health Limited has announced a change in the director’s interest, specifically involving Gerard Paul Fogarty AO. On March 4, 2025, 332,000 shares were acquired indirectly through on-market trades by Amanda Dorothy Fogarty, Gerard Fogarty’s spouse, at a price of $0.075 per share. This acquisition marks a significant change in the director’s relevant interests in securities, which previously stood at nil, potentially impacting the company’s governance and stakeholder interests.
Vitura Health Limited has announced a change in the director’s interest, with Rebecca Jayne Wilson, a director and shareholder of Parker and Wilson Investment Pty Ltd, acquiring 228,000 shares. This acquisition was conducted through on-market trades, reflecting a strategic increase in her indirect interest in the company.
Vitura Health Limited announced its H1 FY2025 financial results and will present them in an investor webinar. The company’s operations, particularly through its Canview platform, are poised for growth with its comprehensive healthcare ecosystem that integrates various services, enhancing efficiency for stakeholders. The announcement signifies Vitura’s strategic positioning in the digital health and medicinal cannabis industry, potentially impacting its market presence and stakeholder engagement.
Vitura Health Limited has issued 5,787,037 fully paid ordinary shares to the owners of Code4 Cannabis Pty Ltd as part of the acquisition of the Canview software platform. This strategic move is expected to bolster Vitura’s capabilities in the cannabis technology space, potentially enhancing its market position and offering new opportunities for stakeholders.
Vitura Health Limited has announced the quotation of 5,787,037 fully paid ordinary securities on the Australian Securities Exchange (ASX). This issuance is part of a transaction previously announced, potentially impacting the company’s market presence and offering new opportunities for stakeholders.
Vitura Health Limited has completed the acquisition of the Canview platform from Code4 Cannabis Pty Ltd, allowing it to fully control and develop the platform. This acquisition is expected to enhance Vitura’s technological capabilities and reduce costs, aligning with its strategic goals. The company has issued shares and made cash payments as part of the settlement, and will withdraw legal proceedings against C4C. This move strengthens Vitura’s position in the digital health industry and supports its growth strategy.
Vitura Health Limited reported a 4.5% increase in revenue for H1 FY2025, reaching $62.7 million, despite facing industry-wide price compression in the medicinal cannabis market. The company’s strategic acquisitions and the growth of its telehealth business are key components of its strategy reset program, which aims to enhance operational efficiency and expand patient access, although net profit after tax declined due to acquisition costs and market challenges.
Vitura Health Limited has released its financial report for the half-year ending December 31, 2024. The report includes comprehensive financial statements and declarations, highlighting the company’s commitment to reconciliation with Traditional Owners in Australia. This financial disclosure provides stakeholders with insights into the company’s performance and future outlook, although it includes cautionary notes about forward-looking statements.
Vitura Health Limited reported a decrease in net profit for the half-year ended 31 December 2024, attributed to declining average selling prices and gross margin pressures in the medicinal cannabis industry. Despite these challenges, the company saw a significant increase in revenue from medical consultations and services, driven by the full integration of Doctors on Demand. Vitura is investing in strategic acquisitions and platform development to stabilize margins and enhance its market position, while also managing its financial liabilities and optimizing working capital.
Vitura Health Limited has completed the acquisition of Candor Medical, a provider of innovative prescription treatments including medicinal cannabis through telehealth consultations. This acquisition, supported by a $5.17 million placement, aims to enhance Vitura’s service offerings and drive growth. By integrating Candor Medical into its operations, Vitura strengthens its position in the digital health sector, expanding its reach and capabilities in delivering healthcare solutions. The acquisition is expected to add significant value to shareholders and enhance service delivery to its growing patient base.
Vitura Health Limited has announced an update regarding the proposed issue of securities. The company has provided a more accurate date for the issuance of shares, which is a revision to their previous announcement. This update is part of Vitura Health’s compliance with ASX listing rules and reflects their ongoing efforts to keep stakeholders informed about significant operational developments.
Hortican Inc., formerly known as Cronos Group Holdings Inc., has announced a change in its substantial holding in Vitura Health Limited, an ASX-listed company. This change was a result of dilution following the issuance of new shares by Vitura Health, which reduced Hortican’s voting power from 10.06% to 8.40%. This shift in voting power could impact Hortican’s influence over company decisions and reflects a strategic adjustment in its investment portfolio.
Vitura Health Limited has reported a change in the interests of a substantial holder, Elizabeth Sarah Jansen, representing the Stanford Investment Trust. The change resulted from a dilution following the issuance of a significant share placement to Charlie Shahin AO, which affected Jansen’s voting power, decreasing it from 19.55% to 17.27%. This adjustment could influence stakeholder dynamics and voting outcomes in future company decisions.
AFO Investments Pty Ltd has become a substantial holder in Vitura Health Limited, a company with ACN 629 071 594, as of February 11, 2025. The substantial holding involves 74,814,757 ordinary shares, granting AFO Investments an 11.39% voting power, which may impact the company’s governance and decision-making processes.
Vitura Health Limited, listed on the ASX under the ticker VIT, has issued 74,814,757 fully paid ordinary shares through a placement to AFO Investments Pty Ltd, associated with high-net-worth investor Professor Charlie Shahin AO. This strategic move indicates a potential influx of capital that could enhance Vitura’s financial standing and market operations, with compliance to relevant legal provisions ensuring transparency for stakeholders.
Vitura Health Limited announced the quotation of 74,814,757 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of previously disclosed transactions and is expected to enhance the company’s visibility and accessibility in the market, potentially impacting its market positioning and stakeholder engagement.
Vitura Health Limited has announced a proposed issue of 74,814,757 fully paid ordinary securities. This move is part of a placement or other type of issue, which signifies a strategic effort to leverage capital markets for expansion or operational funding, potentially influencing its market position and shareholder value.
Vitura Health Limited has announced the acquisition of Candor Medical, a prominent medicinal cannabis clinic business in Australia, expanding its healthcare service offerings and patient base significantly. This strategic acquisition positions Vitura as a leading provider in the medicinal cannabis clinic industry, leveraging Candor’s expertise and extensive patient network to enhance its specialty healthcare services and support growth in patient consultations, ultimately broadening its impact on the Australian digital health landscape.
Vitura Health Limited announced a $5.1 million investment from Professor Khalil Shahin through a share subscription agreement with AFO Investments. This investment will fund the purchase of Candor Medical and other expansion plans, expected to significantly boost Vitura’s revenue and earnings. The involvement of Shahin, a notable business leader, validates Vitura’s growth strategy and market potential, marking a positive impact on the company’s operations and stakeholder confidence.
Vitura Health Limited has requested a trading halt on its securities pending an announcement about a potential acquisition and capital raising. This halt is expected to remain in place until the announcement is made or until normal trading resumes on February 13, 2025. This move indicates that Vitura Health is likely looking to expand its operations and strengthen its financial position, which could have significant implications for its stakeholders.